Dihydroquinolinones for medical treatment

Patent metadata

Field	Value
Publication number	US-12091397-B2
Application number	US-202217878753-A
Country	US
Kind code	B2
Filing date	Aug 1, 2022
Priority date	Sep 4, 2017
Publication date	Sep 17, 2024
Grant date	Sep 17, 2024

Abstract

The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

First claim

We claim:

1. A method for the treatment of cancer comprising administering an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof to a patient in need thereof;
wherein
X 1 is CH or N;
X 2 is CH or N;
X 3 is CH or N,

wherein one of X 1 , X 2 or X 3 is N and the other two are CH;
R 1 is selected from the group consisting of
i) —C(═O)—R 6 ;
ii) heterocyclyl;
iii) heterocyclyl, substituted by 1 or 2 substituents individually selected from R 10 ;
iv) aryl; and
v) aryl, substituted by 1 or 2 substituents individually selected from R 9 ;

R 2 is H, or R 1 and R 2 together with the nitrogen they are attached to form a heteroaryl, which is optionally substituted by 1 or 2 substituents individually selected from R 3 ;
R 3 is selected from the group consisting of:
i) —(CH 2 ) 0-1 -aryl substituted by 1 or 2 substituents selected from R 4 ;
ii) —(CH 2 ) 0-2 —N(R 3c )C(═O)—C 3-7 cycloalkyl;
iii) amino-C 1-6 alkyl;
iv) —C(═O)N(R 3a ,R 3b );
v) C(═O)O—C 1-6 alkyl;
vi) C 1-6 alkyl; and
vii) —C 3-7 cycloalkyl;

R 3a is selected from the group consisting of hydrogen and C 1-6 alkyl;
R 3b is selected from the group consisting of hydrogen and C 1-6 alkyl; or R 3a and R 3b form together with the nitrogen to which they are attached form a heterocycloalkyl;
R 3c is hydrogen;
R 4 is selected from the group consisting of amino, —C(═O)N(R 3a ,R 3b ), C 1-6 alkoxy, C 1-6 alkyl, halo-C 1-6 alkyl, and hydroxy-C 1-6 alkyl;
R 6 is selected from the group consisting of
i) unsubstituted aryl;
ii) unsubstituted heteroaryl; and
iii) heteroaryl substituted by 1 or 2 substituents selected from R 7 ;

R 7 is selected from the group consisting of
i) unsubstituted heteroaryl; and
ii) heteroaryl substituted by 1 or 2 substituents selected from R 8 ;

R 8 is C 1-6 alkyl;
Y is CH 2 or NH;
R 9 is selected from the group consisting of
i) C 1-6 alkyl; and
ii) —C(═O)O—C 1-6 alkyl;

R 10 is selected from the group consisting of
i) C 1-6 alkyl; and
ii) —C(═O)O—C 1-6 alkyl.

2. The method of claim 1 , wherein X 1 is N.

3. The method of claim 1 , wherein X 2 is N.

4. The method of claim 1 , wherein X 3 is N.

5. The method of claim 1 , wherein R 3 is aryl substituted by 1 or 2 substituents selected from R 4 , wherein R 4 is selected from the group consisting of —C(═O)N(R 3a ,R 3b ), C 1-6 alkyl, and C 1-6 alkoxy.

6. The method of claim 1 , wherein R 3 is-C(═O)N(R 3a ,R 3b ).

7. The method of claim 6 , wherein R 3a is hydrogen and R 3b is C 1-6 alkyl.

8. The method of claim 7 , wherein R 3b is methyl.

9. The method of claim 1 , wherein R 1 is-C(═O)—R 6 .

10. The method of claim 1 , wherein R 1 is heterocyclyl.

11. The method of claim 1 , wherein R 1 is heterocyclyl, substituted by 1 or 2 substituents individually selected from R 10 .

12. The method of claim 1 , wherein R 1 is aryl.

13. The method of claim 1 , wherein R 1 is aryl, substituted by 1 or 2 substituents individually selected from R 9 .

Assignees

• C4 Therapeutics Inc

Inventors

• Norcross Roger
• Britschgi Adrian
• Dey Fabian
• Goergler Annick
• Kusznir Eric Andre
• Wichert Moreno Attilio

Classifications

• C07D495/14

  Ortho-condensed systems · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/4375

  the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title

• A61K47/55

  the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug · CPC title